Quick context to catch up fast.
Blue Cross and Blue Shield will stop covering GLP-1 medications prescribed for weight loss on July 1, 2026, unless the Trust chooses another arrangement. The drugs cost the plan $1.019 million last year, about 4% of plan costs, and are used by roughly 77 of 2,600 members. The Trust must notify Blue Cross and Blue Shield by March 1, 2026, and has not yet made a final coverage decision.
Open the committee coverage hubs tied to this summary.
Was this summary helpful?
Your feedback helps us prioritize what to improve next.
The Health Plan Trust is reviewing whether to keep covering GLP-1 weight-loss medications, exclude them, or create a separate coverage arrangement. Continuing coverage is expected to raise premiums by about 8%, while the current plan balance was $4,713,280.32 as of December 31, 2025. Trustees also discussed a reference-based pricing plan that could have premiums about 10% lower than current plans, but no decision was made.
Follow the major takeaways from this briefing.
Action items flagged by the community.
No follow-ups have been shared yet. Add one in the community board below.
Details and records from this meeting.
Fresh records from this municipality.
Know who to contact about the decisions that matter.